Skandinaviska Enskilda Banken (SEB)
KNTE

Skandinaviska Enskilda Banken (SEB)’s Kinnate Biopharma Inc. Common Stock KNTE Stock Holding History

Skandinaviska Enskilda Banken (SEB)’s Portfolio KNTE Stock Details KNTE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-51,200
Closed -$136K – 825
2024
Q1 		$136K Buy
+51,200
New +$127K ﹤0.01% 730

Skandinaviska Enskilda Banken (SEB)'s KNTE Position: Q2 2024 in Review

Skandinaviska Enskilda Banken (SEB) sold out of Kinnate Biopharma Inc. Common Stock (KNTE) in Q2 2024, closing a stake of 51,200 shares — an estimated $136K sold.

Skandinaviska Enskilda Banken (SEB) first reported a position in KNTE in Q1 2024 and held it in 1 quarter. The position peaked at $136K in Q1 2024. 0 funds tracked by Wall St. Rank hold KNTE as of Q2 2024.

  • Skandinaviska Enskilda Banken (SEB) reported no remaining Kinnate Biopharma Inc. Common Stock position as of Q2 2024 after selling out during the quarter.
  • Skandinaviska Enskilda Banken (SEB) sold 51,200 Kinnate Biopharma Inc. Common Stock shares in Q2 2024, an estimated $136K.
  • Skandinaviska Enskilda Banken (SEB) first reported a position in Kinnate Biopharma Inc. Common Stock in Q1 2024 and held it in 1 quarter.
  • Skandinaviska Enskilda Banken (SEB)'s Kinnate Biopharma Inc. Common Stock position peaked at $136K in Q1 2024.
  • 0 funds tracked by Wall St. Rank held Kinnate Biopharma Inc. Common Stock as of Q2 2024.

Based on Skandinaviska Enskilda Banken (SEB)'s 13F filing for Q2 2024, filed 13 Aug 2024.